Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia Launches Review Into Medicines Access & Affordability

Government Says Policy Needs To Take Account Of Innovation And Growing Demand

Executive Summary

Time has taken its toll on Australia’s National Medicines Policy since it was implemented in 2000.

You may also be interested in...



Australia To Address Supply Chain Issues In Medicines Access Review

Stakeholders are being asked to say what they think of plans to future-proof the framework that governs access to medicines and is intended to help bolster the pharmaceutical sector.

Australia Plans New Approval Pathways To Foster Earlier Access To Novel Drugs

The Australian government has come up with a set of proposals for reforming the drug and medical device regulatory framework, which include speeding up access to innovative drugs through expedited and provisional approval mechanisms and greater use of assessments by overseas regulators. The changes will be phased in over a period of about three years and may include some recovery of costs from industry.

Denmark Planning To Impose Drug Stockpiling Obligations From July

A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144740

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel